OncoMatch/Clinical Trials/NCT07209059
PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma
Is NCT07209059 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Nivolumab for hodgkin lymphoma.
Treatment: Nivolumab — This is a single-center, open-label, phase 2 pilot study evaluating the efficacy and safety of a response-adapted first-line treatment strategy for patients with classical Hodgkin lymphoma (cHL) and unfavorable prognostic factors. The FINISH protocol (First-line Immuno-chemotherapy Navigated by Interim PET for Stratification and Hazard minimization In Hodgkin lymphoma) integrates nivolumab into induction therapy and tailors subsequent treatment based on interim PET-CT response. The study also includes exploratory monitoring of circulating tumor DNA (ctDNA) to investigate its role in early response assessment and residual disease detection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hodgkin Lymphoma
Disease stage
Required: Stage IIB (BULKY), III, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: chemotherapy
No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma
Cannot have received: radiation therapy
No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma
Cannot have received: immunotherapy
No prior chemotherapy, radiotherapy, or immunotherapy for lymphoma
Lab requirements
Kidney function
Serum creatinine ≤ 0.2 mmol/L; severe renal impairment (serum creatinine > 0.2 mmol/L) excluded unless lymphoma-related
Liver function
Absence of severe hepatic dysfunction; severe hepatic dysfunction excluded unless directly related to lymphoma
Cardiac function
Absence of severe cardiac dysfunction; congestive heart failure, unstable angina, recent myocardial infarction, or severe cardiac arrhythmias excluded
Adequate organ function, including: Serum creatinine ≤ 0.2 mmol/L; Absence of severe cardiac, pulmonary, hepatic, or renal dysfunction
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify